• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.
【24h】

Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

机译：长期输注白蛋白可改善肝硬化和腹水患者的生存率：一项无盲的随机试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To investigate the effects of long-term albumin administration on survival, recurrence of ascites and onset of other complications. METHODS: One hundred consecutive patients admitted for first-onset ascites were randomized to receive diuretics plus human albumin 25 g/wk in the first year and 25 g every two wk thereafter (group 1) or diuretics alone (group 2).The primary endpoint was survival without liver transplantation. Secondary endpoints were recurrence of ascites and occurrence of other complications. RESULTS: Median follow-up was 84 (2-120) mo. Albumin-treated patients had significantly greater cumulative survival rate (Breslow test=7.05, P=0.0078) and lower probability of ascites recurrence (51% versus 94%, P<0.0001). Chronic albumin infusion resulted in a mean increase in survival of 16 mo. CONCLUSION: Long-term albumin administration after first-onset ascites significantly improves patients' survival and decreases the risk of ascites recurrence.
机译：目的：研究长期服用白蛋白对生存，腹水复发和其他并发症发作的影响。方法：将连续入院的首例腹水的一百例患者在第一年随机接受利尿剂加人白蛋白25 g / wk，之后每两周25 g /人（第1组）或单独使用利尿剂（第2组）。无需肝移植即可生存。次要终点是腹水复发和其他并发症的发生。结果：中位随访时间为84（2-120）个月。用白蛋白治疗的患者具有更高的累积生存率（Breslow检验= 7.05，P = 0.0078）和较低的腹水复发概率（51％对94％，P <0.0001）。慢性白蛋白输注导致平均生存期增加16 mo。结论：初次腹水后长期服用白蛋白可显着提高患者的生存率并降低腹水复发的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号